.-The kidney plays a central role in longterm regulation of arterial blood pressure and salt and water homeostasis. This is achieved in part by the local actions of paracrine and autacoid mediators such as the arachidonic acid-prostanoid system. The present study tested the role of specific PGE 2 E-prostanoid (EP) receptors in the regulation of renal hemodynamics and vascular reactivity to PGE 2 . Specifically, we determined the extent to which the EP 2 and EP 3 receptor subtypes mediate the actions of PGE 2 on renal vascular tone. Renal blood flow (RBF) was measured by ultrasonic flowmetry, whereas vasoactive agents were injected directly into the renal artery of male mice. Studies were performed on two independent mouse lines lacking either EP 2 or EP 3 (Ϫ/Ϫ) receptors and the results were compared with wild-type controls (ϩ/ϩ). Our results do not support a unique role of the EP 2 receptor in regulating overall renal hemodynamics. Baseline renal hemodynamics in EP 2 Ϫ/Ϫ mice [RBF EP 2 Ϫ/Ϫ: 5.3 Ϯ 0.8 ml ⅐ min Ϫ1 ⅐ 100 g kidney wt Ϫ1 ; renal vascular resistance (RVR) 19.7 Ϯ 3.6 mmHg ⅐ ml Ϫ1 ⅐ min ⅐ g kidney wt] did not differ statistically from control mice (RBF ϩ/ϩ: 4.0 Ϯ 0.5 ml ⅐ min Ϫ1 ⅐ 100 g kidney wt Ϫ1 ; RVR ϩ/ϩ: 25.4 Ϯ 4.9 mmHg ⅐ ml Ϫ1 ⅐ min ⅐ 100 g kidney wt Ϫ1 ). This was also the case for the peak RBF increase after local PGE 2 (500 ng) injection into the renal artery (EP 2 Ϫ/Ϫ: 116 Ϯ 4 vs. ϩ/ϩ: 112 Ϯ 2% baseline RBF). In contrast, we found that the absence of EP 3 receptors in EP 3 Ϫ/Ϫ mice caused a significant increase (43%) in basal RBF (7.9 Ϯ 0.8 ml ⅐ min Ϫ1 ⅐ g kidney wt Ϫ1 , P Ͻ 0.05 vs. ϩ/ϩ) and a significant decrease (41%) in resting RVR (11.6 Ϯ 1.4 mmHg ⅐ ml Ϫ1 ⅐ min ⅐ g kidney wt Ϫ1 , P Ͻ 0.05 vs. ϩ/ϩ). Local administration of 500 ng of PGE 2 into the renal artery caused more pronounced renal vasodilation in EP 3 Ϫ/Ϫ mice (128 Ϯ 2% of basal RBF, P Ͻ 0.05 vs. ϩ/ϩ). We conclude that EP 3 receptors mediate vasoconstriction in the kidney of male mice and its actions are tonically active in the basal state. Furthermore, EP 3 receptors are capable of buffering PGE 2 -mediated renal vasodilation. knockout mice; renal blood flow; EP receptor; cAMP; renal circulation; vascular smooth muscle cells
knockout mice; renal blood flow; EP receptor; cAMP; renal circulation; vascular smooth muscle cells THE MAINTENANCE of precisely controlled blood flow within the kidney is essential for regulating appropriate salt and water balance. Paracrine and autacoid mediators play an important role in the control of renal vascular resistance (RVR). PGE 2 has long been recognized as a key product of the arachidonic acid metabolism pathway by cyclooxygenase. PGE 2 is a major arachidonic acid metabolite in the kidney and is known to exert important actions on both renal hemodynamics and tubular transport. It can also be released along with PGI 2 from the vascular endothelium and vascular smooth muscle cells (VSMC) (13, 24, 37) . Among the cyclooxygenase products thromboxane A 2 , PGI 2 , and PGE 2 , PGE 2 is released in greatest abundance from all nephron segments (3) . Infusion of PGE 2 into the kidney commonly causes renal vasodilation, although there are a few reports (2, 10, 11, 16) of reductions in renal hemodynamics, depending on the species, preparations, and doses. Such variability implicates actions of PGE 2 on multiple cell surface receptors in the regulation of renal tubular transport and hemodynamics. PGE 2 elicits its biological effects through interactions with a family of G protein-coupled cell surface receptors. To date, four distinct PGE 2 (E-prostanoid, EP [1] [2] [3] [4] ) receptors have been cloned; each originates from a distinct gene (19) . These EP receptors differ in their amino acid identities, pharmacological characteristics, and signal transduction properties. The existence of unique coupling of EP subtypes to a given signal transduction pathway provides the molecular basis for the diverse and complex physiological actions of PGE 2 . All of the EP receptor subtypes are found in the kidney (12) . More is known about the localization of EP receptors along the nephron than the vasculature. EP 1 and EP 3 receptors are present in cells of the collecting ducts (cortex and medulla) and connecting segments (18, 33) . In situ hybridization and Northern blot studies (4, 12, 33) reveal EP 4 receptor mRNA in rat and human glomeruli. A recent study (18) employing immunohistochemistry reveals EP 3 and EP 4 receptors in human glomeruli. Antibodies localized all four EP receptors to large preglomerular arteries, EP [1] [2] [3] to the afferent arteriole, EP 1 to the efferent arteriole, and all but EP 2 on vasa recta of human kidneys (18) .
The functional roles and patterns of EP receptor control of peripheral vascular resistance in different organs in general and tone of resistance arterioles in the kidney are unknown. It is difficult to predict which specific receptor mediates PGE 2 actions on the renal vasculature in experimental animals. One approach to resolve these issues is to use EP subtype-specific ligands in functional studies. Unfortunately, the weak binding profiles and less-than-ideal selectivity of these compounds limits interpretation of experiments based solely on pharmacological agonist/antagonists action. These imprecise properties complicate their utility in whole animal physiology and render results less than conclusive. To circumvent these limitations, we took a different approach and studied mice in which specific EP receptors were deleted by gene targeting.
The purpose of the present study was to gain insight into the roles of EP 2 and EP 3 receptors in the control of renal hemodynamics in the mouse. Steady-state and dynamic responses of renal blood flow (RBF) were recorded with the use of an ultrasonic flow probe in EP 2 -or EP 3 -deficient (EP 2 Ϫ/Ϫ and EP 3 Ϫ/Ϫ, respectively) mice. We tested the hypotheses that the inability of selected EP receptors to function would affect the renal microcirculation during basal conditions and/or in response to administered PGE 2 . 2 Ϫ/Ϫ and EP 3 Ϫ/Ϫ mice. EP 2 Ϫ/Ϫ and EP 3 Ϫ/Ϫ animals were generated as previously described (9, 35) and maintained on a 129 background. Genotypes were determined by Southern blot analysis. We maintained 129 mice in the University of North Carolina, Chapel Hill animal facility as controls. Only 4-to 5-mo-old male mice were studied. All animal experiments were performed according to approved institutional guidelines.
MATERIALS AND METHODS

Generation of EP
RBF measurements. Surgical procedures were performed as described previously (28, 29) . In brief, a polyethylene (PE-10) catheter was inserted into the right jugular vein for the administration of 4.7 g/dl BSA in saline to maintain constant plasma oncotic pressure during surgery (10 l/min) and then reduced to 2 l/min for the duration of an experiment. A second catheter was placed in the left carotid artery to monitor systemic arterial blood pressure with a transducer (Gulton-Statham P23 dB).
Blood flow in the left kidney was measured continuously by using a noncannulating ultrasonic flowmeter system (Transonic Systems; Ithaca, NY) interfaced with a 5-mm V-shaped probe around the left renal artery. This system has been previously validated in mice by our laboratory (29, 30) . A PE-10 catheter, pulled to a smaller diameter with the tip bent at 90°, was inserted into the abdominal aorta, and its tip was placed ϳ0.5 mm into the left renal artery. Saline was infused continuously into the renal artery (2 l/min), except during bolus injections of vasoactive agents. Placement of the catheter tip at the origin of the renal artery did not affect RBF. There was a 30-min stabilization period after the 60-to 90-min surgical procedures, followed by an observation period of 2-3 h. PGE 2 (Cayman Chemical; Ann Arbor, MI) was resuspended in 100% ethanol at a final concentration of 50 mg/ml. We then used this solution to prepare the various dilutions using saline. The highest concentration of ethanol was 0.1% vol/vol (500 ng/10 l bolus). Thirty seconds before the injection of bolus (10 l), the saline infusion rate into the renal artery was increased to 50 l/min. At 2-min postinjection, the saline infusion was returned to 2 l/min.
Data analysis. RBF measurements and arterial blood pressure readings were recorded by using NotebookPro software (Labtech; Andover, MA) and then transferred into a spreadsheet and analyzed with the use of statistical software (GraphPad; San Diego, CA). All of the data presented are means Ϯ SE. Statistical analyses were performed with the use of Student's t-test and linear regression by least-squares analysis (GraphPad). P Ͻ 0.05 was considered statistically significant.
RESULTS
EP 3 Ϫ/Ϫ mice altered baseline renal hemodynamics.
To assess the contribution of individual EP receptors to resting levels of renal hemodynamics, baseline RBF was compared among age-matched controls (ϩ/ϩ), EP 2 Ϫ/Ϫ, and EP 3 Ϫ/Ϫ male mice. There were no significant differences in animal body weight, kidney weight, or mean arterial blood pressure among genotypes (Table 1 ). RBF and RVR were similar in control mice and EP 2 Ϫ/Ϫ mice. An important finding was that the absence of functional EP 3 receptors (EP 3 Ϫ/Ϫ mice) had a significant effect on renal hemodynamics. Baseline RBF was increased 43% in EP 3 Ϫ/Ϫ compared with wild-type mice (Fig. 1 ). Because arterial pressure was similar in both groups, RVR was reduced in the EP 3 Ϫ/Ϫ mice by almost 50% (Fig. 1 ). These data suggest that EP 3 receptors mediate tonic renal vasoconstriction in these animals under resting conditions. In marked contrast, EP 2 receptors appear to have little, if any, discernable effect on basal renal hemodynamics.
EP 3 Ϫ/Ϫ mice display increased renal responsiveness to PGE 2 . RBF studies were conducted to evaluate RVR and assess the functional response to PGE 2 injected directly into the renal artery of mice lacking EP 2 or EP 3 receptors. In these studies, renal vascular reactivity in response to receptor activation was assessed utilizing a combination of continuous measurement of Values are means Ϯ SE; n ϭ no. of mice at an average age of 5 mo. EP, E-prostanoid. * P Ͻ 0.05 vs. wild-type and EP 2 Ϫ/Ϫ mice.
RBF and drug delivery directly into the renal artery of the experimental kidney (29, 30) . This approach allows for the study of local hormonal effects on the renal circulation without systemic effects of the agonists on arterial pressure. By design, mean arterial blood pressure was unaffected by intrarenal injection of PGE 2 in all experiments.
Vehicle administration reflecting the ethanol content of the 500-ng PGE 2 bolus had no effect on RBF in any group (Fig. 2) . Figure 2 shows individual representative tracings of transient RBF responses to bolus injection of PGE 2 (500 ng) into the renal artery. The general shape of the vasodilatory response to PGE 2 was similar in all groups. PGE 2 caused a significant increase in RBF in wild-type mice, with a maximum increase at 100-110 s. RBF returned to baseline within 5-10 min. Mean arterial pressure was not affected by PGE 2 injection, remaining constant at all times during the experimental period. Thus the recorded changes in RBF reflect inverse changes in RVR during the PGE 2 -induced responses.
Group averages for the maximum vasodilator effect of PGE 2 (500 ng) recorded in all three groups of mice are presented in Fig. 3 . PGE 2 produced a similar amount of vasodilation in EP 2 Ϫ/Ϫ and wild-type mice [116 Ϯ 4% (n ϭ 3) and 112 Ϯ 2% of baseline RBF (n ϭ 6), respectively]. It is possible that a difference exists between EP 2 Ϫ/Ϫ and ϩ/ϩ mice that could not be detected due to the sample size of our experiments. In contrast, deletion of the EP 3 Ϫ/Ϫ receptor had a profound effect on the renal response to PGE 2 . The maximum RBF response was appreciably greater (128 Ϯ 2% of baseline RBF; n ϭ 5) in the absence of a functional EP 3 receptor than in either of the other two groups (P Ͻ 0.05 vs. ϩ/ϩ or EP 2 Ϫ/Ϫ). In addition, the integrated area under the response curve was significantly greater in the EP 3 Ϫ/Ϫ mice than wild-type or EP 2 Ϫ/Ϫ animals. Thus the difference in the integrated RBF response was virtually identical to that observed for peak changes in RBF. These results suggest that EP 3 but not EP 2 receptors contribute to the PGE 2 -mediated vascular responsiveness in the murine kidney.
Dose-dependent responsiveness to PGE 2 in EP 3 Ϫ/Ϫ animals. To further explore the differences in renal reactivity to PGE 2 in EP 3 Ϫ/Ϫ mice, we examined RBF responses to a range of PGE 2 doses (25-500 ng). All tested doses elicited renal vasodilation in all groups. As 2 . Effects of EP 3 receptor mutation on renal hemodynamic responses to PGE 2 . RBF was recorded continuously in anesthetized mice from 0 to 300 s during a 500-ng PGE 2 injection into the renal artery; arterial pressure was unchanged. s, ϩ/ϩ mice (n ϭ 5); ‚, EP 3 Ϫ/Ϫ mice (n ϭ 6); and shaded line, vehicle. EP 3 Ϫ/Ϫ (n ϭ 2) and ϩ/ϩ (n ϭ 2). Values are means Ϯ SE. shown in Fig. 4 , wild-type mice exhibited a maximal increase in RBF (111 Ϯ 2% of control RBF) with 25 ng of PGE 2 . No additional RBF increase was recorded between 25 and 500 ng PGE 2 in ϩ/ϩ mice. Higher doses of PGE 2 (Ն1,000 ng) compromised the systemic hemodynamic stability of the animals, preventing us from utilizing these results.
In contrast, EP 3 Ϫ/Ϫ mice displayed a more readily discernable dose-dependent increase in RBF responsiveness to PGE 2 . The effects of 25 ng PGE 2 were slightly greater in EP 3 Ϫ/Ϫ mice (117 Ϯ 3% basal RBF) than in wild-type controls. The exaggerated response in EP 3 Ϫ/Ϫ mice became more pronounced as the dose of PGE 2 was increased, with 500 ng of PGE 2 producing a greater increase in RBF (128 Ϯ 2 vs. 112.3 Ϯ 2.1% control RBF in control mice) (Fig. 4) .
DISCUSSION
Our studies focused on the role of EP 2 and EP 3 receptors in the control of whole kidney hemodynamics. We focused on these specific subtypes because they have been shown to be present in the kidney and EP 2 -and EP 3 -deficient mice are available on the same 129 genetic backgrounds. The contribution of genetic background is an important consideration with any gene targeting experiment (21) . Therefore, intergroup comparisons can be made in these studies without background genes contributing to data variability.
Although general actions of PGE 2 are well characterized, very little is known about which EP receptor subtypes mediate the biological effects of this prostanoid. With regard to EP receptor actions on the cardiovascular system, we have demonstrated previously (1) in mice that activation of EP 2 receptors is responsible for a systemic depressor response to intravenous injection of PGE 2 . In contrast, PGE 2 -mediated activation of EP 3 receptors causes an increase in mean systemic arterial pressure. The present study extends these findings by characterizing the extent to which EP 2 and EP 3 receptors contribute to the regulation of the microcirculation in the kidney.
Renal vascular reactivity in vivo was investigated by using a recently refined approach in which injection of PGE 2 into the renal artery was combined with continuous measurement of RBF with a miniaturized ultrasound flow transducer. Our results indicate that the EP 3 receptor contributes importantly to the baseline renal hemodynamics by enhancing vasomotor tone. EP 3 Ϫ/Ϫ mice exhibit a 43% increase in baseline RBF and a 41% decrease in RVR independent of changes in systemic arterial blood pressure. On the other hand, the EP 2 receptor does not appear to be a major contributor to resting renal vasomotor tone as basal RBF was independent of EP 2 receptor deletion. The absence of detectable differences in our experiments between EP 2 Ϫ/Ϫ and ϩ/ϩ mice is strongly suggestive that the EP 2 receptors are not present in the majority of renal cortical resistance vessels of male mice, or if present, receptor-mediated vasodilation is undetectable in our experimental conditions.
The same general pattern of contribution was observed in renal vascular reactivity to exogenous PGE 2 . Injection of PGE 2 into the renal artery of wild-type mice produced net renal vasodilation as RBF rose 10-15% above baseline levels. This degree of renal vasodilation was also observed in EP 2 Ϫ/Ϫ or EP 3 Ϫ/Ϫ mice in response to relatively low doses of PGE 2 (25 (32, 36) . Thus EP 3 receptors may antagonize the stimulatory effect of G ␣s -coupled EP receptors. Agonist-dependent activation of EP 1 and EP 3 receptors produces an increase in cytosolic calcium concentration in most nonvascular cell types tested to date. Therefore, EP 1 -and EP 3 -dependent stimulation of intracellular second messengers are predicted to 
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induce VSMC contraction and increase vascular resistance. In VSMC of the rat tail artery, PGE 2 is reported (26) to modulate both intracellular cAMP and calciumdependent pathways leading to the regulation of voltage-dependent rectifier K ϩ channels and modulation of vascular tone. However, the identity of specific EP subtypes involved in these processes is unknown.
In the absence of a detectable phenotypic effect of EP 2 receptor mutation on whole kidney hemodynamics, the remaining G␣ s -coupled EP 4 receptors might be expected to mediate vasodilation by virtue of their ability to stimulate [cAMP] i production. Therefore, it is reasonable to conclude that EP 4 receptors are the predominant EP receptor subtype most likely to mediate PGE 2 -dependent vasodilation in control wild-type animals. The net vasodilatory action of renal PGE 2 and its ability to buffer vasoconstrictor agents more effectively in control than in genetic hypertension has been previously established in animal models (6, 7) . In this setting, the vasodilatory effects of PGE 2 were reduced in 6-wk-old spontaneously hypertensive rats (SHR) compared with aged-matched Wistar-Kyoto (WKY) controls (6) . There is evidence of a defective EP receptor G s -coupled (stimulation of cAMP production) signaling pathway in the renal vasculature of SHR. In vitro studies reveal that PGE 2 stimulation produces weaker-than-normal increases in [cAMP] i in isolated preglomerular arterioles of young SHR versus WKY mice. In vivo RBF studies (8) support this view.
Recently, we (1) described the impact of EP 2 and EP 3 receptor mutations on the effects of PGE 2 in the systemic circulation. Both of these receptors contributed significantly to the PGE 2 -dependent actions on the regulation of arterial blood pressure. Intravenous injection of PGE 2 injected elicited a 25-mmHg reduction in mean arterial pressure in wild-type control animals. In EP 2 Ϫ/Ϫ mice, the same dose of PGE 2 caused a smaller 10-mmHg depressor response, suggesting that EP 2 receptors are vasodilatory and contribute to a decrease in total peripheral resistance, possibly through proposed activation of G s proteins and increases in [cAMP] i . There was an accentuated vasodepressor response in male EP 3 Ϫ/Ϫ consistent with a constrictor action of EP 3 receptors in the peripheral vasculature, perhaps mediated through activation of G i and subsequent reductions in [cAMP] i and/or stimulation of intracellular calcium. It is not known which vascular beds contribute to the systemic pressor effects of PGE 2 . Our current study provides new information about the importance of EP 3 receptors in mediating renal vasoconstriction and the apparent absence of EP 2 actions on the renal vasculature of male mice. Two recent reports (25, 34) described the role of EP receptors in transducing PGE 2 effects in the rat renal preglomerular microcirculation. These investigators provided convincing evidence supporting the role of EP 1 and/or EP 3 and EP 4 receptors in kidney hemodynamics. These observations are consistent with our present report. This is especially relevant in view of documented differences in the actions of PGE 2 among species. The physiological response to PGE analogues is quite different between isolated preparations of rabbit and piglet saphenous veins (15) , suggesting that individual EP receptors contribute differently to the PGE 2 -dependent vasomotor activity of these preparations. This situation is not unique to saphenous vein preparations. Differences in PGE 2 potencies were also reported between human and rabbit preparations of basilar arteries (22) . In human artery preparations, PGE 2 and its analogue 16,16-dimethyl PGE 2 (EP 3 ϾEP 4 ϾEP 2 ) cause contractions. In contrast, in the rabbit artery, both compounds cause relaxation. Therefore, caution must be exercised in extrapolating results from one species to the next (e.g., mouse to human) as relative levels of EP receptors or efficacy in receptor-evoked signal transduction may differ appreciably.
Our whole kidney RBF results pertain to total vascular resistance in vivo. It would be of interest to extend our studies to discern which specific vascular segments in the renal microcirculation are responsible for the observed changes in total resistance. In this regard, identification of EP receptor location and function in the afferent and efferent arterioles is worthy of further investigation as are relative contributions in superficial and juxtamedullary nephron populations.
Nonsteroidal anti-inflammatory drugs (NSAIDs) are potent inhibitors of the cyclooxygenase enzymes, and their anti-inflammatory effects occur through inhibition of the production of prostanoids such as PGE 2 (31) . PGE 2 can act as a major determinant of renal vascular tone by acting as a vasodilator and counteracting the effects of vasoconstrictor agents. Administration of NSAIDs can cause marked renal vasoconstriction (8) and reversible acute renal failure (5, 23) in elderly patients and patients with congestive heart failure or volume depletion. Recently, cyclooxygenase-2-specific inhibitors have also been shown (27) to cause significant transient renal vasoconstriction. The undesired side effects of subtype and nonsubtype-specific NSAIDs may be due in part to the reduction of PGE 2 from the circulation (38) . In this situation, the actions of vasoconstrictors become unrestrained and dominant, resulting in a deleterious attenuation of renal perfusion. This is especially relevant in view of the counteracting vasodilatory effect of PGE 2 with respect to vasoconstrictors such as ANG II, endothelin, norepinephrine, and vasopressin (17, 20) . Alternatively, there is evidence (19) suggesting that EP 3 isoforms may be able to exert effects independent of agonist. It is interesting to speculate on the implications and the therapeutic potential of using specific EP receptor agonists and/or antagonists in disease states and during NSAID therapy.
In summary, we have measured RBF with the use of an ultrasonic flowmeter system in anesthetized mice. Compared with wild-type control animals, resting RBF is elevated in EP 3 receptor-deficient mice but is normal in mice with EP 2 receptors rendered nonfunctional by gene mutation. Deletion of putative vasodilatory EP 2 receptors had no discernable effect on renal vasodilation elicited by intrarenal PGE 2 . In contrast, more H331 pronounced vasodilation was clearly observed in EP 3 Ϫ/Ϫ mice. Our results suggest a very weak or nonexistent role for EP 2 receptors in either baseline or PGE 2 -dependent vascular responsiveness. The ablation of gene expression by homologous recombination is a powerful tool for the study of gene function. However, it is important to appreciate that the phenotype of any "knockout" study may not only reflect on the absence of the targeted gene, but also on the potential compensation of other genes that may be upregulated in these genetically modified animals. For example, a significant upregulation of PGE 2 biosynthesis is noted in fibroblasts isolated from PGH 2 synthase (PGHS 1 Ϫ/Ϫ or PGHS 2 Ϫ/Ϫ) animals compared with their wild-type controls (14) . In mice, our data suggest that EP 3 receptors are present on renal resistance vessels and mediate vasoconstriction that plays a role in damping the strength of vasodilation triggered by PGE 2 . On the basis of our current knowledge of signal transduction, it is reasonable to postulate that the major vasodilatory action of PGE 2 is mediated by another EP receptor, such as the EP 4 receptor that couples to a G ␣s protein and stimulates [cAMP] i . The vasoconstrictor EP 3 receptor may play an important role in the control of renal hemodynamics.
